- eczematous skin lesions
- typical histopathologic features: spongiosis, acanthosis, and dermal infiltrate
B cells play a major role in the AE pathogenesis. Monoclonal anti-CD20 antibody therapy (rituximab) leads to a decrease in B cells, and therefore, could improve AE.
In a small study of 6 patients, rituximab led to an impressive improvement of AE in patients with severe disease within 4-8 weeks. Although peripheral blood B cells were undetectable due to rituximab use, skin B cells were decreased by 50% only.
Atopic Dermatitis Treatment - Illustrated (click here for full size image).
Anti-CD20 (rituximab) treatment improves atopic eczema. Volume 121, Issue 1, Pages 122-128 (January 2008).